WW INTERNATIONAL, INC.

WW International, Inc. announced a partnership with the American Heart Association to support the Healthy Living BEYOND Weight™ Study. This collaboration aims to deepen the understanding of real-world weight health and improve care for individuals living with obesity or who are overweight. WW is connecting its members to this research opportunity, highlighting its comprehensive care model that integrates medical support, nutrition, and behavioral guidance, particularly for those using GLP-1 medications. Internal analyses showed that WW Med+ members on GLP-1s who engaged in behavioral support lost significantly more weight.

WW International, Inc. and CheqUp announced a significant expansion of their partnership in the UK, integrating clinical and behavioral weight management support. This allows UK Weight Watchers members to access CheqUp's medical weight loss program, while CheqUp members continue to utilize the Weight Watchers app and GLP-1 Companion Programme. The collaboration aims to provide a more holistic and connected weight health experience, aligning with the growing recognition of GLP-1 medication benefits and the need for comprehensive support.

WW International, Inc. announced a Settlement Agreement with its former President and Chief Executive Officer, Tara Comonte, following her resignation effective March 31, 2026. The agreement, entered into on May 14, 2026, outlines a total settlement payment of $1,850,000 to Ms. Comonte, paid in two installments, along with $150,000 for her attorneys' fees. The agreement also includes customary mutual releases of claims, a cooperation covenant, mutual non-disparagement, and confidentiality provisions.

WW International reported a net loss of $52.0 million for Q1 2026, an improvement from $72.6 million in Q1 2025, but revenue declined by 10.9% to $168.3 million. The financial statements reflect fresh start accounting following the company's emergence from Chapter 11 bankruptcy in June 2025, impacting comparability, especially for the significantly higher net loss per share of $(5.20). The company's Behavioral business saw a significant revenue decrease, while its Clinical business experienced growth, but overall cash flow from operations turned negative. Both goodwill for the Behavioral reporting unit and the trade name intangible asset were identified as being at risk for impairment.

WW International, Inc. announced its first quarter 2026 financial results, reporting $168 million in revenue and a net loss of $52.0 million. While total revenue declined and Adjusted EBITDA was a loss, the company saw strong growth in its Clinical business, with subscribers up 46% and revenue up 32% year-over-year. The company also reaffirmed its full-year 2026 financial guidance and announced plans to reduce its debt by $42 million through a $37 million cash prepayment in Q2 2026.

WW International, Inc. announced it will begin offering access to Novo Nordisk's newly available Ozempic® pill (semaglutide) through its Med+ offering. This addition provides members with a once-daily GLP-1 option for adults with type 2 diabetes, supported by a clinically backed program. The company will assist members with insurance navigation, potentially reducing monthly prescription costs to as low as $25 for eligible individuals, and offers comprehensive support including tailored nutrition guidance and coaching.

WW International, Inc. announced its 2026 Annual Meeting of Shareholders will be held virtually on Friday, June 12, 2026, at 10:00 a.m. Eastern Time. Shareholders will consider and act upon the election of six director nominees, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2026, and an advisory vote to approve named executive officer compensation. The record date for voting is April 20, 2026. The company also noted its emergence from Chapter 11 restructuring on June 24, 2025, and a change in its fiscal year end to December 31.

WW International, Inc. announced its intention to prepay and reduce its outstanding term loan by up to $40 million. This prepayment includes $25 million to $30 million for the annual cash sweep due June 24, 2026, and a voluntary solicitation for up to $10 million at a discount. The company also reaffirmed its first quarter 2026 subscriber estimates and full year 2026 financial guidance, emphasizing strengthened liquidity and deleveraging efforts.

WW International, Inc. announced its plan to prepay up to $40 million of its outstanding term loan, comprising $25 million to $30 million from its annual cash sweep and a voluntary solicitation for up to $10 million at a discount. Concurrently, the company reaffirmed its first quarter 2026 end-of-period subscriber estimates and full-year 2026 financial guidance. This move reflects progress in strengthening liquidity and deleveraging the balance sheet, with expectations of continued cash generation through the year.

WW International, Inc. announced it will release its first quarter 2026 financial results before market open on Thursday, May 7, 2026. The company will host a conference call to discuss these results at 8:30 a.m. ET on the same day. A webcast of the call will be accessible on the company's corporate website, with a replay available for at least 90 days.